Xilio Therapeutics, Inc. (XLO) NASDAQ

8.20

-0.05(-0.61%)

Updated at June 02 04:00PM

Currency In USD

Valuation

Market Cap748.98M
Enterprise Value618.4M
P/E Ratio-42.83
PEG Ratio-0.47
Price/Sales Ratio0.92
Price/Book Ratio18.48
Enterprise/Revenue-1.77
Enterprise/EBITDA2.32

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin-0.59
Operating Margin-0.79

Management Effectiveness

Return On Assets-0.19
Return On Equity-1.17

Income Statement

Revenue43.77M
Revenue/Share0.33
Gross Profit42.23M
EBITDA-40.44M
Net Income-35.04M
Diluted EPS-4.19

Balance Sheet

Total Cash150.33M
Total Cash/Share0.92
Total Debt6.64M
Total Debt/Equity0.09
Current Ratio3.59
Book Value Per Share0.44

Price History

52-Week Change-16.33
52-Week High12.74
52-Week Low6.47
Moving Average 50 Days8.29
Moving Average 200 Days9.28

Statistics

Average Volume48,191
Shares Outstanding5.98M
% Held by Institutions1.6

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:14
Last Split DateMarch 16, 2026